Hyalgan

Hyalgan is a prescription intra‑articular injection containing sodium hyaluronate, a high‑molecular‑weight hyaluronic acid, supplied as a sterile solution for joint administration. The product is marketed in the European Union and is classified as a viscosupplement used to manage osteoarthritis. By delivering hyaluronic acid directly into the affected joint, Hyalgan aims to restore the normal viscoelastic properties of synovial fluid, supporting joint function and comfort for patients.

Hyalgan is indicated for symptomatic relief of osteoarthritis in weight‑bearing joints where conventional therapy has been insufficient.

- Osteoarthritis of the knee, administered as a series of intra‑articular injections. - Osteoarthritis of the hip, provided when oral analgesics are inadequate. - Adjunct to physical therapy to improve joint mobility. - Option for patients who cannot tolerate non‑steroidal anti‑inflammatory drugs. - May reduce the need for surgical intervention in selected cases.

Adverse reactions to Hyalgan are generally related to the injection procedure and the presence of hyaluronic acid in the joint.

Common: - Mild to moderate pain at the injection site during or shortly after administration. - Local swelling or effusion that resolves within a few days. - Warmth or tenderness around the treated joint. - Transient stiffness lasting up to 48 hours.

Serious: - Joint infection (septic arthritis) requiring medical intervention. - Severe allergic reaction, including rash, urticaria, or anaphylaxis. - Persistent joint effusion or inflammatory synovitis. - Rapidly progressive osteoarthritis possibly linked to repeated injections. - Rare cases of cartilage damage or joint deterioration.

Before initiating Hyalgan therapy, clinicians should evaluate patient history and joint condition.

- Do not inject into a joint with active infection, septic arthritis, or skin lesions over the injection site. - Use caution in patients with a history of hypersensitivity to hyaluronic acid or its excipients. - Assess renal function in patients with severe kidney disease, as clearance of hyaluronate may be altered. - Avoid use in pregnant or breastfeeding women unless the potential benefit justifies the risk. - Monitor for signs of joint inflammation or infection after each injection. - Consider alternative treatments for patients with severe joint instability or mechanical derangement.

Hyalgan has limited systemic absorption, but certain medications may affect safety or efficacy.

Avoid: - Concurrent intra‑articular corticosteroid injections in the same joint within a short interval, as this may increase infection risk. - Use of intra‑articular antibiotics immediately before or after Hyalgan without proper aseptic technique. - Administration in joints that have recently received arthroscopic surgery (within 4 weeks).

Use with caution: - Anticoagulant or antiplatelet therapy (e.g., warfarin, clopidogrel) due to potential for prolonged bleeding at the injection site. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask early signs of infection. - Systemic immunosuppressants, which could increase susceptibility to joint infection. - High‑dose vitamin C supplements, as they may theoretically affect hyaluronate metabolism. - Concurrent disease‑modifying osteoarthritis drugs (DMOADs) pending clinical judgment.